Reuters logo
FDA to review Genzyme's Lemtrada resubmission
May 30, 2014 / 6:31 AM / 4 years ago

FDA to review Genzyme's Lemtrada resubmission

PARIS, May 30 (Reuters) - Sanofi said on Friday the U.S. Food and Drug Administration had agreed to review Genzyme’s resubmission of its application for its Lemtrada drug for the treatment of relapsing forms of multiple sclerosis.

A six-month review period has been assigned for the Lemtrada resubmission and Genzyme expects an FDA action in the fourth quarter, Sanofi said in a statement. (Reporting by Dominique Vidalon)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below